To the full analysis
Asker Healthcare Group stock: growth
ASKER.STAsker Healthcare Group reported $1.68B in revenue for fiscal 2025, up 11.7% on the prior year, up 15.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.7%
per year from 2021 to 2025, per share 16.9%
Earnings (Annual rate)
1.3%
per year from 2021 to 2025, per share 0.6%
Free cash flow (Annual rate)
30%
per year from 2021 to 2025, per share 31.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | |
|---|---|
| Revenue | 15.7% |
| Revenue per share | 16.9% |
| Earnings | 1.3% |
| Earnings per share | 0.6% |
| Free cash flow | 30.0% |
| Free cash flow per share | 31.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2021 | $937.94M | $46.83M | $25.87M |
| 2022 | $1.17B | $43.12M | $85.53M |
| 2023 | $1.35B | $20.36M | $90.34M |
| 2024 | $1.51B | $36.1M | $88.14M |
| 2025 | $1.68B | $49.33M | $74M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Mar 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.